Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01540201
Other study ID # 2011-12-033-002
Secondary ID
Status Completed
Phase N/A
First received February 16, 2012
Last updated December 24, 2013
Start date February 2012
Est. completion date October 2012

Study information

Verified date December 2013
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority South Korea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Pulmonary gas exchange disturbance is a common anesthetic problem during one-lung ventilation (OLV) for thoracic surgery. The inverse-ratio ventilation (IRV), which prolongs the inspiratory time greater than expiratory time, can be applied for adult respiratory distress syndrome. The effect of IRV is to improve gas-exchange status by increasing mean airway pressure and alveolar recruitment. We tried to evaluate the effect of IRV during OLV with lung protective strategy.


Description:

Pulmonary gas exchange disturbance is a common anesthetic problem during one-lung ventilation (OLV) for thoracic surgery. Continuous positive airway pressure or positive end-expiratory pressure are usually applied to improve this disorder including hypoxia, but these methods are not enough. The inverse-ratio ventilation (IRV), which prolongs the inspiratory time greater than expiratory time, can be applied for adult respiratory distress syndrome. The effect of IRV is to improve gas-exchange status by increasing mean airway pressure and alveolar recruitment. The application of IRV during OLV has not been performed to our knowledge, and there is a possibility of IRV to improve oxygenation during OLV. There is a possibility of increase of auto-PEEP, or air trapping in subjects with chronic obstructive pulmonary disease, but this kind of auto-PEEP can be overcome by external PEEP. Therefore, we tried to evaluate the effect of IRV during OLV with lung protective strategy.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- patients undergoing elective lung lobectomy surgery.

- the duration of one-lung ventilation is more than one hour.

- subjects with more than twenty years old.

Exclusion Criteria:

- subjects with past history of pneumothorax, asthma

- Age under 20, more than 70 years.

- Patients with ischemic heart disease, valvular heart disease

- patients with hemodynamic unstability

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)


Intervention

Other:
Conventional I:E ratio
conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
I:E = 1:1 ratio
I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary arterial CO2 partial pressure arteial CO2 partial pressure 10 minutes after induction of general anesthesia No
Primary arterial CO2 partial pressure arteial CO2 partial pressure 30 minutes after start of one-lung ventilation No
Primary arterial CO2 partial pressure arteial CO2 partial pressure 60 minutes after start of one-lung ventilation No
Primary arterial CO2 partial pressure arteial CO2 partial pressure 15 min after restart of TLV No
Primary arterial CO2 partial pressure arteial CO2 partial pressure 1 hour after the end of surgery No
Secondary arterial O2 partial pressure arterial O2 partial pressure 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation, 1 hour after the end of surgery No
Secondary Mean airway pressure Mean airway pressure 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary tidal volume (exhaled) tidal volume (exhaled) 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary hemodynamic parameters systolic/ diastolic blood pressure, heart rate, mean blood pressure 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary end-tidal CO2 partial pressure end-tidal CO2 partial pressure 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary respiratory compliance Dynamic compliance, Static compliance 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary Dead space physiologic dead space / tidal volume (VD/VT) 10 min after induction, 30 and 60 min after start of one lung ventilation, 15 min after restart of two-lung ventilation No
Secondary work of breathing work of breathing 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary peak inspiratory pressure peak inspiratory pressure 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary plateau pressure plateau pressure 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary positive end-expiratory pressure positive end-expiratory pressure 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
Secondary minute ventilation minute ventilation 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation No
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk